Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
Amolyt Pharma
Amryt Pharma Plc
CohBar Inc
Exscien Corp
Glycomantra Inc
Hanmi Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
NorthSea Therapeutics BV
The Healthy Aging Co
Insulin Resistance - Drug Profiles
ALF-5755 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-3404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target hOGG1 for Acute Lung Injury and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosabutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOTS-c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Immunology, Insulin Resistance and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFD-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Insulin Resistance, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Insulin Resistance, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Insulin Resistance - Pipeline by Amolyt Pharma, 2021
Insulin Resistance - Pipeline by Amryt Pharma Plc, 2021
Insulin Resistance - Pipeline by CohBar Inc, 2021
Insulin Resistance - Pipeline by Exscien Corp, 2021
Insulin Resistance - Pipeline by Glycomantra Inc, 2021
Insulin Resistance - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, 2021
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, 2021
Insulin Resistance - Pipeline by The Healthy Aging Co, 2021
Insulin Resistance - Dormant Projects, 2021
Insulin Resistance - Dormant Projects, 2021 (Contd..1)
Insulin Resistance - Dormant Projects, 2021 (Contd..2)